53355-29-6

Usage

Uses

Used in Scholarly Research:
4-(5-Formyl-furan-2-yl)-benzoic acid methyl ester is used as a research compound for investigating its chemical properties and potential applications in various scientific fields.
Used in Laboratory Settings:
In laboratories, 4-(5-Formyl-furan-2-yl)-benzoic acid methyl ester serves as a test substance to explore its reactivity, stability, and interactions with other compounds, contributing to the understanding of its potential uses and limitations.

InChI:InChI=1/C13H10O4/c1-16-13(15)10-4-2-9(3-5-10)12-7-6-11(8-14)17-12/h2-8H,1H3

Upstream product

• 619-44-3 methyl 4-iodobenzoate 
• 378185-02-5 (5-(diethoxymethyl)furan-2-yl)boronic acid 
• 1899-24-7 5-bromo-2-furancarboxaldehyde 
• 99768-12-4 4-methoxycarbonylphenylboronic acid 
• 13716-12-6 tri-tert-butyl phosphine 
• 27329-70-0 5-formylfurane-2-boronic acid 
• 2689-65-8 5-iodofuran-2-carbaldehyde 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 14047-29-1 4-carboxyphenylboronic acid 
• 67-56-1 methanol 
• 39245-15-3 4-(5'-formylfuran-2'-yl)benzoic acid 
• 13529-27-6 2-(diethoxymethyl)furan 

Downstream Products

• 765937-84-6 3-[5-(4-methoxycarbonylphenyl)-2-furyl]acrylic acid 
• 39245-15-3 4-(5'-formylfuran-2'-yl)benzoic acid 
• 1280723-04-7 4-(5-((4-oxo-3-(2-methylphenyl)-2-(2-methylphenylimino)thiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid 
• 503837-98-7 sortin1 

Relevant academic research and scientific papers

Synthesis of alkyne-tagged and biotin-tagged Sortin1 as novel photoaffinity probes

Sortin1 is an inhibitor of vesicular biogenesis and transport, which is shared among eukaryotes and plants with an unknown mode of action. Toward exploration of its target proteins, we developed alkyne as well as biotin conjugated photoaffinity probes derived from Sortin1. Due to the presence of phenylketone moiety, Sortin1 was anticipated to serve as a photoreactive group in a similar manner to a commonly used photoreactive group, benzophenone. The core structure based on 5-oxo-1,4-dihydroindenopyridine was constructed in one step using three-component Hantzsch dihydropyridine synthesis. We demonstrated that Sortin1 displayed photocrosslinking reactivity against a model binding protein, which would be useful for capturing and detecting binding proteins.

Synthesis and biological evaluation of novel rhodanine-based structures with antiviral activity towards HHV-6 virus

An increased awareness of diseases associated with Human herpesvirus 6 (HHV-6) infection or reactivation has resulted in a growing interest in the evaluation of the best treatment options available for the clinical management of HHV-6 disease. However, no

Visible light induced cross-coupling synthesis of asymmetrical heterobiaryls using Pd/CeO2 nanocomposite photocatalyst

A simple, mild and green approach has been developed for the synthesis of asymmetrical heterobiaryls under the irradiation of visible light without any oxidants and promoting reagents through using Pd/CeO2 nanocomposite photocatalyst. This method can tolerate considerable functional groups such as electron-donating groups and electron-withdrawing groups through C–C cross-coupling. Moreover, we obtain the products with moderate yields in an efficient way. Finally, a plausible mechanism is proposed.

Structure-based discovery of new selective small-molecule sirtuin 5 inhibitors

Human sirtuin 5 (SIRT5) is a protein deacylase regulating metabolic pathways and stress responses and is implicated in metabolism-related diseases. Small-molecule inhibitors for SIRT5 are sought as chemical tools and potential therapeutics. Herein, we proposed a customized virtual screening approach targeting catalytically important and unique residues Tyr102 and Arg105 of SIRT5. Of the 20 tested virtual screening hits, six compounds displayed marked inhibitory activities against SIRT5. For the hit compound 19, a series of newly synthesized (E)-2-cyano-N-phenyl-3-(5-phenylfuran-2-yl)acrylamide derivatives/analogues were carried out structure–activity relationship analyses, resulting in new more potent inhibitors, among which 37 displayed the most potent inhibition to SIRT5 with an IC50 value of 5.59?±?0.75?μM. The biochemical studies revealed that 37 likely acts via competitive inhibition with the succinyl-lysine substrate, rather than the NAD+ cofactor, and it manifested substantial selectivity for SIRT5 over SIRT2 and SIRT6. This study will aid further efforts to develop new selective SIRT5 inhibitors as tools and therapeutics.

D-3-phosophoglycerate dehydrogenase allosteric inhibitor and application thereof

The invention discloses a D-3-phosophoglycerate dehydrogenase allosteric inhibitor and an application thereof. The structure of the D-3-phosophoglycerate dehydrogenase allosteric inhibitor is shown in a formula I defined in the specification, wherein R1,

Substituted 2-cyano-3-phenyl furan-acrylamide derivative, preparation method and application thereof

The invention provides a substituted 2-cyano-3-phenyl furan-acrylamide derivative. The structural formula is shown as formula I. The invention also provides a preparation technology and an application of the substituted 2-cyano-3-phenyl furan-acrylamide derivative. A pharmacodynamic test proves that the compound provided by the invention has better inhibitory activity to SIRT5, especially optimal inhibitory activity to compound 17, the inhibitory activity is obviously better than that of the presently reported SIRT5 small-molecule inhibitors, such as nicotinamide, the substituted 2-cyano-3-phenyl furan-acrylamide derivative provided by the invention has an accurate pharmacodynamic effect and a new drug selection is supplied for the clinic.

Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors

Abstract Glycolysis is drastically increased in tumors and it is the main route to energy production with a minor use of oxidative phosphorylation. Among the key enzymes in the glycolytic process, LDH is emerging as one of the most interesting targets for the development of new inhibitors. In this context, in the present work, we carried out a virtual screening procedure followed by chemical modifications of the identified structures according to a "hit-to-lead" process. The effects of the new molecules were preliminary probed against purified human LDH-A. The compounds active at low micromolar level were additionally characterized for their activity on some cellular metabolic processes by using Raji human cell line. Within the series, 1 was considered the best candidate, and a more detailed characterization of its biological properties was performed. In Raji cells exposed to compound 1 we evidenced the occurrence of effects usually observed in cancer cells after LDH-A inhibition: reduced lactate production and NAD/NADH ratio, apoptosis. The flow cytometry analysis of treated cells also showed cell cycle changes compatible with effects exerted at the glycolytic level. Finally, in agreement with the data obtained with other inhibitors or by silencing LDH-A expression, compound 1 was found to increase Raji cells response to some commonly used chemotherapeutic agents. Taken together, all these finding are in support of the LDH-A inhibiting activity of compound 1.

USE OF THIAZOLIDINONE DERIVATIVES AS ANTIANGIOGENIC AGENTS

The invention relates to the use of compounds of general formula (I), in which R1, R2 and X are as defined in the description for the preparation of pharmaceutical compositions for the treatment of pathologies in which inhibition of the interaction between HIF-1α and p300 is beneficial, in particular as antiangiogenic medicaments for the therapy of solid tumors.

Preparation of highly functionalized heterocyclic zinc organometallics via a Li(acac)-catalysis of the I/Zn-exchange reaction

The reaction of i-Pr2Zn in the presence of catalytic amount of Li(acac) in NMP with various functionalized heterocyclic iodides provides new polyfunctional diheteroarylzincs, which undergo smooth Negishi cross-coupling reactions and CuCN-2LiCl-